Nemaura Medical Inc.
NMRD · OTC
3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $1 | $0 | $0 |
| % Growth | -84.7% | – | – | – |
| Cost of Goods Sold | $2 | $0 | $0 | $0 |
| Gross Profit | -$1 | $0 | -$0 | $0 |
| % Margin | -1,916.3% | 31.7% | – | – |
| R&D Expenses | $2 | $2 | $2 | $2 |
| G&A Expenses | $6 | $6 | $3 | $3 |
| SG&A Expenses | $6 | $6 | $3 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | $0 | $0 | $0 |
| Operating Expenses | $8 | $8 | $5 | $5 |
| Operating Income | -$10 | -$8 | -$5 | -$5 |
| % Margin | -12,454.2% | -1,502.3% | – | – |
| Other Income/Exp. Net | -$5 | -$7 | -$2 | $0 |
| Pre-Tax Income | -$14 | -$14 | -$7 | -$5 |
| Tax Expense | $0 | -$0 | -$0 | -$1 |
| Net Income | -$14 | -$14 | -$6 | -$4 |
| % Margin | -18,358% | -2,755.8% | – | – |
| EPS | -0.57 | -0.59 | -0.28 | -0.2 |
| % Growth | 3.4% | -110.7% | -40% | – |
| EPS Diluted | -0.57 | -0.59 | -0.28 | -0.2 |
| Weighted Avg Shares Out | 25 | 23 | 22 | 21 |
| Weighted Avg Shares Out Dil | 25 | 23 | 22 | 21 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $2 | $0 |
| Interest Expense | $6 | $7 | $2 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$7 | -$7 | -$4 | -$5 |
| % Margin | -9,458.3% | -1,456.7% | – | – |